Last reviewed · How we verify
Extended- release Oxycodone
Extended-release oxycodone binds to opioid receptors in the central nervous system to reduce pain perception.
Extended-release oxycodone binds to opioid receptors in the central nervous system to reduce pain perception. Used for Moderate to severe chronic pain requiring continuous opioid therapy, Cancer pain.
At a glance
| Generic name | Extended- release Oxycodone |
|---|---|
| Sponsor | Hospital Central Dr. Luis Ortega |
| Drug class | Opioid analgesic |
| Target | Mu (μ) opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Oxycodone is a semi-synthetic opioid agonist that binds primarily to mu (μ) opioid receptors in the brain and spinal cord, inhibiting pain signal transmission and modulating pain perception. The extended-release formulation provides sustained drug delivery over 12 hours, allowing for less frequent dosing compared to immediate-release formulations. This mechanism makes it suitable for chronic moderate to severe pain management.
Approved indications
- Moderate to severe chronic pain requiring continuous opioid therapy
- Cancer pain
Common side effects
- Constipation
- Nausea
- Dizziness
- Drowsiness
- Vomiting
- Headache
- Respiratory depression
Key clinical trials
- Opioid Use Post-Discharge After Ambulatory Distal Arm Surgery (NA)
- Hip Arthroscopy Postoperative Opioid Demands (NA)
- Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) (PHASE1)
- Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101) (PHASE1)
- Evaluation of Oral PF614 Relative to OxyContin (PF614-102) (PHASE1)
- An Analysis of the Efficacy of a Pre-Emptive Multimodal Pain Regimen in Reducing Acute Post-Operative Pain and Narcotic Pain Medication Requirements in Spine Surgery (PHASE4)
- Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade (PHASE4)
- Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |